This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by von Wichert, G. Articles by Seufferlein, T. Search for Related Content PubMed PubMed Citation Articles by von Wichert, G. Articles by Seufferlein, T.

Insulin-like Growth Factor-I Is an Autocrine Regulator of Chromogranin A Secretion and Growth in Human Neuroendocrine Tumor Cells¹

Departments of Internal Medicine I [G. v. W., S. K., B. O. B., G. A., T. S.] and Internal Medicine II [P. M. J.], University of Ulm, D-89081 Ulm, Germany; Department of Veterinary Medicine, Genzentrum, D-80539 Munich, Germany [A. H., E. W.]; Department of Internal Medicine/Division of Hepatology and Gastroenterology, Charite, Humboldt University of Berlin, D-13086 Berlin, Germany [B. W.]; and Department of Surgery, Martin Luther University, D-06099 Halle, Germany [H. D.]

Carcinoid tumors are predominantly found in the gastrointestinal tract and are characterized by hypersecretion of various substances, including bioamines and neuropeptides, leading to functional tumor disease. Here, we demonstrate that human BON carcinoid tumor cells express functionally active insulin-like growth factor-I (IGF-I) receptors and secrete IGF-I, suggesting an autocrine action of this growth factor. The IGF-I receptor was functionally active. IGF-I stimulated phosphatidylinositol 3-kinase (PI3-kinase), p70 S6 kinase (p70^s6k), and extracellular signal-regulated kinase 2 activity in BON cells. Furthermore, immunoneutralization of endogenously released IGF-I markedly reduced the high basal activity of p70^s6k and extracellular signal-regulated kinase 2 in serum-starved BON cells. Exogenously added IGF-I induced a marked increase in chromogranin A secretion, a marker protein for neuroendocrine secretion, by a process that was largely dependent on PI3-kinase activity. In addition, immunoneutralization of endogenously released IGF-I markedly reduced basal chromogranin A release by BON cells. Thus, the autocrine IGF-I loop regulates basal neuroendocrine secretion in BON cells. Next, we investigated the role of IGF-I as a growth promoting agent for BON cells. Our data demonstrate that IGF-I stimulates anchorage-dependent and anchorage-independent growth of BON cells by a pathway that involves PI3-kinase, mammalian target of rapamycin/p70^s6k, and mitogen-activated protein kinase kinase 1 activity. Interestingly, mitogen-activated protein kinase kinase 1 activity was less important for anchorage-independent growth of BON cells. Endogenously released IGF-I was found to be largely responsible for autonomous growth of BON cells in serum-free medium and for the constitutive expression of cyclin D1 in these cells. In conclusion, IGF-I is a major autocrine regulator of neuroendocrine secretion and growth of human BON neuroendocrine tumor cells. Because our data also demonstrate that a significant proportion of neuroendocrine tumors express the IGF-I receptor and its ligand, interference with this pathway could be useful in the treatment of hypersecretion syndromes and growth of human neuroendocrine tumors.

This article has been cited by other articles:

				Y.-C. Wang, E. Gallego-Arteche, G. Iezza, X. Yuan, M. R Matli, S.-P. Choo, M. B Zuraek, R. Gogia, F. C Lynn, M. S German, et al. Homeodomain transcription factor NKX2.2 functions in immature cells to control enteroendocrine differentiation and is expressed in gastrointestinal neuroendocrine tumors Endocr. Relat. Cancer, March 1, 2009; 16(1): 267 - 279. [Abstract] [Full Text] [PDF]

				G. Vitale, P. M. van Koetsveld, W. W. de Herder, K. van der Wansem, J. A. M. J. L. Janssen, A. Colao, G. Lombardi, S. W. J. Lamberts, and L. J. Hofland Effects of type I interferons on IGF-mediated autocrine/paracrine growth of human neuroendocrine tumor cells Am J Physiol Endocrinol Metab, March 1, 2009; 296(3): E559 - E566. [Abstract] [Full Text] [PDF]

				J. C. Yao, A. T. Phan, D. Z. Chang, R. A. Wolff, K. Hess, S. Gupta, C. Jacobs, J. E. Mares, A. N. Landgraf, A. Rashid, et al. Efficacy of RAD001 (Everolimus) and Octreotide LAR in Advanced Low- to Intermediate-Grade Neuroendocrine Tumors: Results of a Phase II Study J. Clin. Oncol., September 10, 2008; 26(26): 4311 - 4318. [Abstract] [Full Text] [PDF]

				A. Moreno, A. Akcakanat, M. F Munsell, A. Soni, J. C Yao, and F. Meric-Bernstam Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors Endocr. Relat. Cancer, March 1, 2008; 15(1): 257 - 266. [Abstract] [Full Text] [PDF]

				I Duran, R Salazar, O Casanovas, V Arrazubi, E Vilar, L. Siu, J Yao, and J Tabernero New drug development in digestive neuroendocrine tumors Ann. Onc., August 1, 2007; 18(8): 1307 - 1313. [Abstract] [Full Text] [PDF]

				K. H. Weylandt, M. Nebrig, N. Jansen-Rosseck, J. S. Amey, D. Carmena, B. Wiedenmann, C. F. Higgins, and A. Sardini ClC-3 expression enhances etoposide resistance by increasing acidification of the late endocytic compartment Mol. Cancer Ther., March 1, 2007; 6(3): 979 - 986. [Abstract] [Full Text] [PDF]

				M. Kidd, G. N Eick, I. M Modlin, R. Pfragner, M. C Champaneria, and J. Murren Further delineation of the continuous human neoplastic enterochromaffin cell line, KRJ-I, and the inhibitory effects of lanreotide and rapamycin J. Mol. Endocrinol., January 1, 2007; 38(1): 181 - 192. [Abstract] [Full Text] [PDF]

				M. Hopfner, V. Baradari, A. Huether, C. Schofl, and H. Scherubl The insulin-like growth factor receptor 1 is a promising target for novel treatment approaches in neuroendocrine gastrointestinal tumours. Endocr. Relat. Cancer, March 1, 2006; 13(1): 135 - 149. [Abstract] [Full Text] [PDF]

				M. Kunnimalaiyaan, K. Traeger, and H. Chen Conservation of the Notch1 signaling pathway in gastrointestinal carcinoid cells Am J Physiol Gastrointest Liver Physiol, October 1, 2005; 289(4): G636 - G642. [Abstract] [Full Text] [PDF]

				E. K. Nakakura, V. R. Sriuranpong, M. Kunnimalaiyaan, E. C. Hsiao, K. E. Schuebel, M. W. Borges, N. Jin, B. J. Collins, B. D. Nelkin, H. Chen, et al. Regulation of Neuroendocrine Differentiation in Gastrointestinal Carcinoid Tumor Cells by Notch Signaling J. Clin. Endocrinol. Metab., July 1, 2005; 90(7): 4350 - 4356. [Abstract] [Full Text] [PDF]

				N. Li, Q. Wang, J. Li, X. Wang, M. R. Hellmich, S. Rajaraman, G. H. Greeley Jr., C. M. Townsend Jr., and B. M. Evers Inhibition of mitochondrial gene transcription suppresses neurotensin secretion in the human carcinoid cell line BON Am J Physiol Gastrointest Liver Physiol, February 1, 2005; 288(2): G213 - G220. [Abstract] [Full Text] [PDF]

				R. S. Sippel, J. E. Carpenter, M. Kunnimalaiyaan, S. Lagerholm, and H. Chen Raf-1 activation suppresses neuroendocrine marker and hormone levels in human gastrointestinal carcinoid cells Am J Physiol Gastrointest Liver Physiol, July 7, 2003; 285(2): G245 - G254. [Abstract] [Full Text] [PDF]

				A. Hoeflich, R. Reisinger, H. Lahm, W. Kiess, W. F. Blum, H. J. Kolb, M. M. Weber, and E. Wolf Insulin-like Growth Factor-binding Protein 2 in Tumorigenesis: Protector or Promoter? Cancer Res., December 1, 2001; 61(24): 8601 - 8610. [Full Text] [PDF]